EAN 2023 | Safinamide improves motor and non-motor symptoms in fluctuating Parkinson’s disease patients

Safinamide mechanism of action includes a unique dopaminergic and non-dopaminergic component through reversible inhibition of the monoamine oxidase-B enzyme and modulation of glutamate release. Carlo Cattaneo, DBSc CAAAN, Zambon SpA, Bresso, Italy, discusses a study that analyzed data from four safinamide studies (016, 018, SETTLE, and XINDI) to investigate the effects of safinamide versus placebo on motor complications, pain, and mood in patients with Parkinson’s disease. Safinamide was able to improve motor symptoms, control motor complications, and improve non-motor symptoms. These favorable effects are due to the double mechanisms of actions that act on both dopaminergic and glutaminergic pathways. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.